Sign in to view content

Dual Targeting VEGF/Ang3 Surrobody in an Experimental Model of Neovascularization

Jeffrey L. Olson, MD

Video
Published 2019

Jeffrey Olson, MD

Related

FIDO Study: 10-Year Outcomes of Eyes Receiving Continuous, Fixed-Interval Dosing of Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Ivan J. Suner, MD, MBA
Annual Meeting Talks
2019
Endolaserless Vitrectomy with Intravitreal Aflibercept
Dennis M. Marcus, MD
Updates from the Field
2017
What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study
Roger A. Goldberg, MD, MBA
Updates from the Field
2019

Category: AMD-Neovascular

See more